Brivaracetam

證據等級: L5

預測適應症: 10 個

Brivaracetam: Focal Epilepsy — No TxGNN Repurposing Prediction Available

One-Sentence Summary

Brivaracetam is a third-generation antiepileptic drug (AED) approved for the treatment of partial-onset (focal) seizures in adults and children. The current Evidence Pack contains no TxGNN-generated repurposing predictions for this drug, and the Germany market authorization query returned zero records — indicating that the data pipeline is incomplete and a full repurposing evaluation cannot be conducted at this stage.

Quick Overview

Item	Content
Original Indication	Partial-onset (focal) seizures / Epilepsy
Predicted New Indication	— (no prediction generated)
TxGNN Prediction Score	—
Evidence Level	L5 — Model prediction data unavailable
Germany Market Status	Not marketed (0 records retrieved)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No new indication has been predicted by TxGNN for Brivaracetam in this Evidence Pack, so a formal mechanism-to-indication bridging analysis cannot be performed.

Detailed mechanism of action data is not available in the Evidence Pack. Based on publicly available information, Brivaracetam selectively binds to synaptic vesicle protein 2A (SV2A) with high affinity — a mechanism shared with levetiracetam but with approximately 15–30× greater SV2A binding selectivity. SV2A modulates synaptic vesicle cycling and neurotransmitter release, which is the basis for its antiseizure activity. This target has attracted exploratory interest in other neurological conditions (e.g., neuropathic pain, traumatic brain injury), but no repurposing signal has been generated by the current pipeline.

The absence of predictions may reflect missing input features in the knowledge graph or a data retrieval issue upstream, rather than a lack of biological rationale. Manual pipeline review is recommended before concluding that no repurposing candidates exist.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — no TxGNN predictions, no Germany regulatory records, and no safety data were successfully loaded. A repurposing evaluation requires at minimum one scored indication candidate; proceeding without it would be speculative.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for DB05541 (BRIVARACETAM) to generate ranked indication candidates
Retrieve Germany/EMA authorization data — Brivaracetam (Briviact®) received EMA approval in 2016; the zero-record result suggests a data retrieval failure rather than true absence
Obtain MOA data from DrugBank API (DB05541) to enable mechanism-to-indication bridging
Download and parse package insert from regulatory authority to populate key warnings and contraindications
Re-evaluate once a scored predicted indication and complete safety profile are available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.